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Abstract
Objectives: We aimed to update the 2010 evidence- and 
consensus-based national clinical guideline on the diagnosis 
and management of uncomplicated urinary tract infections 
(UTIs) in adult patients. Materials and Methods: An interdis-
ciplinary group consisting of 17 representatives of 12 medi-
cal societies and a patient representative was formed. Sys-
tematic literature searches were conducted in MEDLINE, 
 EMBASE, and the Cochrane Library to identify literature pub-
lished in 2010–2015. Results: We provide 75 recommenda-
tions and 68 statements in the updated evidence- and con-
sensus-based national clinical guideline. The diagnostics 
part covers practical recommendations on cystitis and py-
elonephritis for each defined patient group. Clinical exami-
nations, as well as laboratory testing and microbiological 
pathogen assessment, are addressed. Conclusion: In accor-
dance with the global antibiotic stewardship initiative and 
considering new insights in scientific research, we updated 
our German clinical UTI guideline to promote a responsible 
antibiotic use and to give clear hands-on recommendations 
for the diagnosis and management of UTIs in adults in Ger-
many for healthcare providers and patients.
© 2018 S. Karger AG, Basel
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Uncomplicated, bacterial, community-acquired uri-
nary tract infections (UTIs), including cystitis and pyelo-
nephritis, are among the most common infections in the 
outpatient setting. Data on antibiotic consumption in un-
complicated UTIs from the German Barmer health insur-
ance, one of the largest health insurance funds, on pre-
scribing practice in the treatment of cystitis are in sharp 
contrast to the recommendations of the German clinical 
guideline on uncomplicated UTIs of 2010 [1] not to use 
fluoroquinolones in uncomplicated cystitis. In contrast to 
the guideline recommendations, primarily fluoroquino-
lones (48%) were prescribed [2].
Antibiotic resistance is a growing global problem that 
leads to significant challenges and costs in the health care 
system [1–5]. The resistance level of pathogens against 
commonly used antibiotics of uncomplicated UTIs has sig-
nificantly increased in recent years. Recognition of this fact 
has led to an international re-evaluation of therapeutic rec-
ommendations in uncomplicated UTIs [4]. In accordance 
with this global initiative and the achievements in the an-
tibiotic stewardship movement, we updated our German 
clinical UTI guideline to promote a responsible antibiotic 
use in the management of UTIs in adults in Germany.
The German Society for Urology (DGU) was heading 
the update process of the interdisciplinary Association of 
Scientific Medical Societies in Germany S3 guideline. 
Funding by the pharmaceutical industry was strictly 
avoided; the conflicts of interest by the members of the 
guideline group were disclosed and discussed openly. The 
German Association of Scientific Medical Societies in 
Germany (AWMF) S3 guideline is free for download 
available in a short and long version on the website of the 
AWMF (http://www.awmf.org/leitlinien/detail/ll/043–
044.html) [6]. The category S3 refers to the German guide-
line classification form, where S3 represents the highest 
methodological standard and involves both evidence- and 
consensus-based concepts to achieve guideline recom-
mendations from an interdisciplinary panel group [7].
The guideline recommendations address all medical 
specialties involved in the diagnostics, therapy, manage-
ment, and prevention of acute uncomplicated UTIs (Ta-
ble 1), for example, general practitioners, gynecologists, 
infectious disease specialists, microbiologists, nephrolo-
gists, urologists, and laboratory physicians. 
Here, we present the main content of the updated 
guideline in 2 parts. Part I focuses on the recommenda-
tions regarding the definition of patient groups and the 
diagnostics of uncomplicated bacterial UTI acquired in 
the outpatient setting in adult patients. Part II will cover 
the treatment of acute episodes of cystitis and pyelone-
phritis and prophylaxis of recurrent UTIs.
Objective
The objective of the study was to update the 2010 evi-
dence- and consensus-based national guideline on the di-
agnostics and management of uncomplicated UTIs in adult 
patients. Specific objectives were (a) to promote a rational 
use of antimicrobial substances, (b) to avoid an inappropri-
ate use of antibiotic therapies (i.e., use without indication), 
and (c) to avoid the development of antibiotic resistances.
Methods
The AWMF S3 clinical guideline is based on an interdisciplin-
ary consensus group consisting of 17 representatives of 12 medical 
societies and a member of a patient organization, thus considering 
all relevant medical specialties involved in the diagnostics and the 
management of UTIs in adult patients (Table 1). 
A systematic literature search was conducted in the databases 
MEDLINE, EMBASE, and the Cochrane Library to identify the lit-
erature published between January 2010 and December 2015. Inter-
national clinical guidelines, systematic reviews, meta-analysis, and 
randomized clinical trials on this topic were considered for inclu-
sion. For specific chapters, like epidemiology, collateral damage, or 
diabetic patients with UTI, individual searches were conducted and 
the experts selected specific literature outside the above-mentioned 
inclusion criteria. The literature searches identified 2,909 publica-
tions, which were screened for inclusion. Finally, 156 publications 
(primary and secondary studies as well as clinical guidelines) were 
considered as relevant. The risk of bias of the included studies was 
assessed using AGREE [8], AMSTAR [9], or the Cochrane tool for 
randomized clinical trials [10]. The Oxford criteria were used for 
the level of evidence ratings (Table 2) [11]. A formal consensus was 
achieved through the nominal group process under the guidance of 
an external moderator from the AWMF with the representatives of 
the participating medical associations. The evidence-based recom-
mendations were developed in a consensus conference.
The following 3 grades of recommendations were categorized:
•	 A: strong recommendation: should/should not (German: “soll”)
•	 B: recommendation: ought to/ought not to (German “sollte”)
•	 C: open recommendation: may be considered
The process of development of the S3 Guideline is illustrated in 
Figure 1.
Definition of UTIs
A UTI is classified as uncomplicated if there are no 
relevant functional or anatomical anomalies in the uri-
nary tract, no relevant renal functional impairment and 
Clinical Practice Guideline: 
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Table 1. Participating medical societies and working groups
Medical Society or working group Participants in the update 2017
German Society of Urology (DGU, Deutsche Gesellschaft für Urologie) – lead organization Dr. J. Kranz
Prof. Dr. K.G. Naber
Dr. S. Schmidt
Dr. L. Schneidewind
Priv. Doz. Dr. W. Vahlensieck
Prof. Dr. F.M.E. Wagenlehner
German Society for General and Family Medicine (DEGAM, Deutsche Gesellschaft für 
Allgemeinmedizin und Familienmedizin)
Prof. Dr. E. Hummers
Priv. Doz. Dr. G. Schiemann
German Society of Gynecology and Obstetrics (DGGG, Deutsche Gesellschaft für 
Gynäkologie und Geburtshilfe)
Prof. Dr. U. Hoyme
Dr. M. Kunze
German Society for Hygiene and Microbiologie (DGHM, Deutsche Gesellschaft für 
Hygiene und Mikrobiologie)
Dr. E. Kniehl
German Society of Infectious Diseases (DGI, Deutsche Gesellschaft für Infektiologie) Dr. S. Helbig
Dr. F. Mandraka
German Society of Nephrology (DGfN, Deutsche Gesellschaft für Nephrologie) Prof. Dr. R. Fünfstück
Prof. Dr. U. Sester
Paul Ehrlich Society for Chemotherapy (PEG, Paul-Ehrlich-Gesellschaft für Chemotherapie) Prof. Dr. R. Fünfstück
Dr. E. Kniehl
Prof. Dr. K.G. Naber
Prof. Dr. F.M.E. Wagenlehner
Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL) Prof. Dr. W. Hofmann
Bundesverband Deutscher Krankenhausapotheker (AKDA) Dr. C. Lebert
CA-Deutschland e.V., Förderverein Interstitielle Zystitis (patient representative) B. Mündner-Hensen
Table 2. Level of evidence after Oxford 2009 classification system [11]
Level of 
evidence
Diagnostics Therapy
Ia Systematic review (SR; with homogeneity) of level 1 
diagnostic studies; clinical decision rule with 1b studies 
from different clinical centres
SR (with homogeneity) of randomized controlled 
studies (RCT)
Ib Validating cohort study with good reference standards, or 
clinical decision rule tested within 1 clinical centre
Individual RCT (with narrow confidence interval)
Ic Absolute SpPins* and SnNouts* All or none principle
IIa SR (with homogeneity) of level >2 diagnostic studies SR (with homogeneity) of cohort studies
IIb Exploratory cohort study with good reference standards, 
clinical decision rule after derivation, or validated only on 
split-sample or databases
Individual cohort study (including low quality RCT)
IIc Outcomes research, ecological studies
IIIa SR (with homogeneity) of 3b and better studies SR (with homogeneity) of case-control studies
IIIb Non-consecutive study, or without consistently applied 
reference standards
Individual case-control study
IV Case-control study, poor or non-independent reference 
standard
Case-series (and poor-quality cohort
and case-control studies)
V Expert opinion without explicit critical appraisal, or based on 
physiology, bench research, or first principles
Expert opinion without explicit critical appraisal, or based on 
physiology, bench research, or first principles* An “Absolute SpPin” is a diagnostic finding whose specificity is so high that a positive result rules-in the diagnosis. An “Absolute SnNout” is a diagnostic 
finding whose sensitivity is so high that a negative result rules-out the diagnosis [11].
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no relevant concomitant disease that would promote 
the UTI, or the risk of developing serious complications 
[3].
•	 Acute uncomplicated cystitis: A lower UTI (cystitis) is 
assumed when the acute symptoms refer only to the 
lower urinary tract, for example, urgency, pain on mic-
turition (dysuria), pollakisuria, and pain above the 
symphysis.
•	 Acute uncomplicated pyelonephritis: An upper UTI 
(pyelonephritis) ought to be assumed if, in the case of 
acute symptoms, flank pain, pain on palpation of the 
flank, and/or fever (>38  ° C) persist.
•	 Asymptomatic bacteriuria: Clinically symptomatic 
UTI is distinguished from asymptomatic bacteri-
uria. The term ‘asymptomatic UTI’ ought not to be 
used.
•	 Recurrent uncomplicated UTIs: A recurrent UTI is as-
sumed if relapse rates of ≥2 symptomatic episodes oc-
cur within 6 months or ≥3 symptomatic episodes with-
in 12 months.
Definition of Patient Groups
The following patient groups with uncomplicated UTI 
ought to be distinguished for diagnostic and therapeutic 
purposes:
•	 Otherwise healthy, non-pregnant premenopausal 
women (reference group).
•	 Otherwise healthy pregnant women.
•	 Otherwise healthy postmenopausal women.
•	 Men with uncomplicated UTI.
•	 Patients with diabetes mellitus.
Diagnostics
Diagnostic methods are designed to detect the pres-
ence of UTIs, but also, when appropriate, to ascertain the 
etiology (bacterial spectrum) that triggered the infection 
and how it can be treated (susceptibility to antibiotics). 
Clinical Examination
As type and frequency of anatomical or symptomatic 
complications may differ in individual patient groups, 
group-specific diagnostic strategies ought to be applied (V).
Women with suspected uncomplicated UTIs should 
be asked if they:
1. Have relevant pain on micturition and urgency
2. Suspect a UTI as a cause themselves
3. Have vaginal discomfort.
If the answer to question 1 and/or 2 is “yes,” a UTI is 
very likely. For vaginal complaints, a differential diagno-
sis should also be considered (A, Ia).
Alternative diagnoses and gynecological examination 
ought to be considered in women who suffer from vaginal 
itching or vaginal discharge (B, Ia): the presence of pain on 
micturition, urgency, and occasional hematuria increases 
the likelihood of a UTI. If one or more of these symptoms 
are present, a positive dipstick (nitrite or leukocyte ester-
ase alone or in combination) further increases the likeli-
hood of a UTI (Ia). Diagnosis without direct patient con-
tact is possible and has been successfully evaluated in some 
studies on telephone management or using an interactive 
computer response system. While this approach proved to 
be feasible in terms of patient satisfaction and cure rates, 
Constitution and invitation of representative and interdisciplinary
guideline panel group
Literature searches: systematic searches and selective literature
inclusion for specific topics
Literature screening and quality appraisal
Guideline content review and content update based on
current evidence
Review and update of statements and recommendations
Finding a panel group consens
External guideline review
Final guideline publication
Fig. 1. Steps in the development of the guideline.
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doctor-patient treatment (telemedicine) has not been in-
vestigated in Germany. Experiences with telemedicine 
from other countries cannot directly be transferred to the 
German healthcare system (Ib).
Diagnostics in Different Patient Groups
In the following, specific recommendations for the di-
agnosis in non-pregnant premenopausal women without 
other relevant concomitant diseases are presented (stan-
dard group). For the other patient groups, the specific 
recommendations on diagnosis are listed in the guideline 
document (http://www.awmf.org/leitlinien/detail/ll/043-
044.html).
Diagnosis of Acute Uncomplicated Cystitis in  
Non-Pregnant Premenopausal Women
If women who have no risk factors for complicated 
UTIs complain of typical symptoms (pain on micturition, 
pollakisuria, urgency), have no vaginal symptoms (itch-
ing, altered discharge), have no fever and no flank pain, 
the presence of an uncomplicated cystitis may be consid-
ered with high probability (IIa).
In the first manifestation of an acute UTI or, if the pa-
tient is unknown to the doctor, a symptom-related medi-
cal examination with clinical examination ought to be 
performed (B, V). The diagnosis of uncomplicated cysti-
tis based on clinical criteria may be considered with high 
probability (sensitivity of 94.7%, specificity of 82.4%) 
with the use of the validated questionnaire (Acute Cystitis 
Symptom Score [ACSS]) [12], which assesses the severity 
of the symptoms and the course of the disease (IIb). The 
validated questionnaire ACSS may be considered to fol-
low the course of cystitis over time and the effect of ther-
apy (IIb) [13]. The ACSS questionnaire is translated and 
validated in several languages (www.acss.world).
In women with uncomplicated, non-recurrent or -re-
fractory cystitis, with clear clinical symptoms, no micro-
biological examination is recommended (IIIc). In symp-
tomatic women, the detection of Escherichia coli in the 
midstream urine, independent of the number of patho-
gens, is predictive for a bacterial UTI. In contrast, the de-
tection of Enterococci and group B Streptococci in the 
midstream urine is not predictive for a UTI (Ib). 
Diagnosis of Uncomplicated Acute Pyelonephritis in 
Non-Pregnant Premenopausal Women
In the diagnosis of uncomplicated acute pyelonephri-
tis in non-pregnant women without other relevant con-
comitant diseases, the clinical examination follows the 
general principles (see above). In addition, a physical ex-
amination and urine examination including a urine cul-
ture should be carried out (A, V). In the diagnosis of un-
complicated acute pyelonephritis in non-pregnant wom-
en without other relevant concomitant diseases, further 
examinations (e.g., sonography) should be performed to 
exclude complicated factors (A, V). 
Diagnosis of Asymptomatic Bacteriuria in  
Non-Pregnant Premenopausal Women
In non-pregnant women without other relevant con-
comitant diseases, screening for asymptomatic bacteri-
uria ought not to be carried out (A, Ia).
Diagnosis of Persistent and Recurrent UTIs in  
Non-Pregnant Premenopausal Women
In patients with persistent hematuria or persistent de-
tection of pathogens other than E. coli, further studies 
such as urethrocystoscopy and further imaging ought to 
be performed (B, V). In patients with recurrent UTIs, a 
urine culture and a single sonography ought to be per-
formed. Further invasive diagnostics ought not to be per-
formed (B, Ib). 
Urine Diagnostic Procedures
The gold standard for the diagnosis of UTI is the urine 
examination, including quantitative urine culture and its 
assessment, with appropriate clinical examinations and 
typical symptom assessment (V).
Urine Dipsticks
In patients with a low pretest probability, a negative 
test for nitrite/leukocytes may be considered to rule out 
UTI with sufficient certainty (IIa). The detection of blood, 
leukocytes, and nitrite independently increases the likeli-
hood of the presence of a UTI. The combination of the 
positive findings further increases the likelihood of the 
diagnosis (Ib).
Urine Microscopy
With urine microscopy, it may be considered that 
UTIs can be largely ruled out, if the investigator has ad-
equate experience (Ia). The centrifugation of the urine for 
the microscopic detection of bacteria does not lead to a 
greater accuracy of the diagnosis (Ib). It may be consid-
ered, that if leukocytes are missing at urine microscopy, a 
UTI can be excluded (IIIb). 
Kranz et al.Urol Int6
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Urine Culture
In patients with typical symptoms, colony counts of 
up to 10.3–10.4 CFU/mL of typical uropathogens can al-
ready be clinically relevant for clinical symptoms (Table 
3) if they were detected in mono cultures (i.e., only one 
type of bacteria) of typical uropathogens (V).
Urine samples for cultural microbiological diagnos-
tics need to be processed immediately. If the sample can-
not be processed immediately, the urine needs to be 
stored at 2°–8  ° C until further examination (V). Quanti-
tative urine culture with species identification and sus-
ceptibility testing is an indispensable prerequisite for tar-
geted therapy, especially in pyelonephritis and recurrent 
UTIs (V).
Flow Cytometry
Urine flow cytometry is a laboratory-based method to 
standardize urine sediment analysis. The automated an-
alyzers are capable to quantify for examples white blood 
counts (WBC) or bacteria. While clinical performance 
with a sensitivity (specificity) of 0.87 (0.67) for WBCs 
and 0.92 (0.60) for bacteria seems promising, a system-
atic review and meta-analysis concluded that due to 
methodological shortcomings further studies are needed 
[14].
Imaging Diagnostics and Endoscopy
For the diagnosis of acute pyelonephritis in healthy 
women without complicating factors, further diagnostic 
procedures are recommended to rule out complicating 
factors (e.g., sonography; V). In women without recur-
rent UTI and without relevant comorbidities, routine 
cystoscopy ought not to be performed (B, IIb).
Differential Diagnosis – Diagnostic Strategies
In the case of non-specific symptoms, or inconsistent 
urine examination, including negative urine culture, oth-
er diagnoses, such as gynecological infections, like chla-
mydia or trichomonas infection, should be considered at 
an early stage (V).
Bacterial Spectrum
The most common cause of uncomplicated UTIs is E. 
coli, followed by Staphylococcus saprophyticus, Klebsiella 
pneumoniae, and Proteus mirabilis. Other pathogens are 
rare (Ia). Enterococci are most commonly found in mixed 
infections. Therefore, their pathogenicity is uncertain in 
uncomplicated UTIs (Ic).
Figure 2 shows the clinical microbiological pathway 
for diagnosis and therapy of symptomatic patients.
Key Messages
Uncomplicated UTIs are responsible for a large pro-
portion of all antibiotic prescriptions and pathogen resis-
tance is increasing worldwide. This is a major challenge 
in health care and therefore requires a responsible and 
restricted handling of antibiotic prescriptions across all 
health care professions.
Patient-reported symptom assessment is a key in the 
diagnostic evaluation of acute cystitis. The validated 
ACSS is an accurate tool for the diagnosis of acute un-
complicated cystitis in women. It may be considered in 
the patient follow-up for clinical outcome assessment and 
in the determination of the effect of therapy.
The performance of a differential diagnosis is impor-
tant in cases of non-specific symptoms, or inconsistent 
urine examination, including negative urine culture, and 
other diagnoses, such as gynecological infections with 
chlamydia or trichomonas, should be considered at an 
early stage of patient examination.
The most common cause of uncomplicated UTIs is E. 
coli, followed by Staphylococcus saprophyticus, Klebsiella 
pneumoniae, and Proteus mirabilis. Other pathogens are 
rare. Urine analysis, including microbiology, is the gold 
Table 3. Cut-off values (colony forming units [CFU]/mL) for the 
diagnosis of different urinary tract infections and asymptomatic 
bacteriuria [15]
Diagnosis Evidence 
of bacteria, 
CFU/mL
Urine collection
Acute uncomplicated cystitis 
in women
103 Midstream urine
Acute uncomplicated 
pyelonephritis
104 Midstream urine
Asymptomatic bacteria 105 In women: evidence 
in 2 consecutively 
midstream urine 
samples. In men: 
evidence in 1 
midstream urine 
sample. For catheter 
urine: 102 CFU/mL
Clinical Practice Guideline: 
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Symptomatic
patient: dysuria,
alguria, pollakisuria,
leukozcturia, fever,
flank pain
Uncomplicated
cystitis of women
with low risk
Other patients, for example,
infection of the upper urinary tract
or complicated urinary tract
infection
Urine culture with antibiogram and
empiric therapy or
Targeted therapy after availability
of antibiogram
Patient with
special indication,
for example, pregnancy or
intervention in the
urinary tract
Clinical decision:
definitive case for
therapy
Nitrite positive
urine?
Leukozcte positive
urine?
 Reevaluation of the clinical symptoms
 Options according to individual decision:
1. Watchful waiting with/without symptomatic therapy
2. Empiric antibiotic therapy
3. Further evaluation, for example, with
 gynecological, nephrological or urological work up
No screening for
asymptomatic bacteriuria
Urine culture with antibiogram,
targeted therapy after
availability of antibiogram
Empiric therapy
culture with antibiogram only
if increase in local resistance
pattern to standard antibiotics
No
No
No
No,
not sure
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Fig. 2. Clinical microbiological pathway for diagnosis and therapy of symptomatic patients. Adapted from the guideline version [6].
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typical symptom assessment. Nevertheless, performing 
urine culture in every patient is economically not feasible; 
therefore, in women who have no risk factors for compli-
cated UTIs, complain of typical symptoms (e.g., pain on 
micturition, frequent urination, urgency), have no vagi-
nal symptoms (itching, altered discharge), have no fever, 
and no flank pain, the presence of an uncomplicated cys-
titis may be considered with high probability.
In patients with persistent hematuria or persistent 
detection of pathogens other than E. coli, further stud-
ies such as urethrocystoscopy and further imaging 
ought to be performed. In patients with recurrent UTIs, 
a urine culture and a single sonography should be per-
formed.
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